Abstract IA007: Design of next generation precision medicine trials using artificial intelligence

Abstract

Abstract A better understanding of cancer biology has enabled the development of molecularly targeted therapies matching molecular alterations that induce tumor proliferation and metastases. Over the last decades, dozens of drugs were approved in various cancer types based on molecular alterations, often producing prolonged efficacy. More recently, some molecular alterations were found to be relevent across cancer types, such as NTRK translocations, thereby defining novel ontologies of cancer populations that are no longer defined by their cancer type but only a molecular alteration/signature. Although drug development is being challenged by these novel ontologies, patient stratification remains quite straightforward with unidimentional treatment algorithms (1 drug for 1 alteration, across or within cancer types). However, the relevance of some other alterations present in several cancer types sometimes differs across cancer types, but also among patients with a same cancer type, highlithing the issue of cancer heterogeneity. This later much more frequent situation supports a precision medicine approach that takes into account comprehensive molecular profiling. What I will try to explain during my talk is that the move from stratified medicine to precision medicine, defined as the individual selection of a treatment based on comprehensive molecular profiling, can only be done by using artificial intelligence. In order to illustrate this provocative statemen, I will review some initiatives that have used artificail intelligence in their study designs. I will finish by presenting the SENTIER project (Strategies to Expedite and Navigate Therapeutic Innovations through patient-centric and knowledge-Enhanced Research), an integrated research platform for early drug development that pursues the aim to accelerate drug development by connecting data from different early phase clinical trials in order to accelerate drug development. Citation Format: Christophe Le Tourneau. Design of next generation precision medicine trials using artificial intelligence [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr IA007.